Skip to main content
Equibles
DYAI logo

DYAI · Dyadic International Inc · Metrics

Track DYAI — free

Use DYAI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DYAI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.34 0.00 (-0.09%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, our management has concluded that there is substantial doubt about our ability to continue as a going concern, which depends upon our obtaining necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due.”
View the 10-Q filed Aug 12, 2026
Market Cap
$12.38M
Shares
36.44M
Volume · Nov 6 67.03K Avg daily vol (3M) 155.84K

DYAI metrics

77 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.34
Market cap
$12.38M

Price action

23 metrics
Price change (1W)
-5.8%
Price change (30D)
-25.5%
Price change (3M)
-66.7%
Price change (6M)
-54.7%
Price change (YTD)
-63.8%
Price change (1Y)
-67.3%
Trailing year
Price change (5Y)
-91.7%
52-week high
$1.47
52-week low
$0.34
Change from 52-week high
-76.9%
Change from 52-week low
+0.0%
Annualized volatility
83.9%
Annualized volatility (3M)
76.5%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.9
RSI (14D)
31.9
Price vs SMA 50
-22.7%
Price vs SMA 200
-54.7%
Avg volume (3M)
157,112
Relative volume
0.5
Average dollar volume
$85,397

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
36.44M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.3×
reciprocal yield 30.7%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-61.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
48.3×
reciprocal yield 2.1%
EV / revenue historical average (5Y)
72.5×
reciprocal yield 1.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
16.2%
Operating margin
-195.1%
Trailing 12 months
Net margin
-200.5%
Gross profit (TTM)
$617,621
Operating profit (TTM)
−$7.42M
Net income (TTM)
−$7.62M
Trailing 12 months
Diluted EPS (TTM)
$-0.21
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.11
Gross profit per diluted share (TTM)
$0.02
Operating profit per diluted share (TTM)
$-0.21
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.21
Operating cash flow per diluted share (TTM)
$-0.21
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.05
Stock compensation per diluted share (TTM)
$0.02
Book value per share
$0.03

Growth

11 metrics
Revenue growth YoY
-0.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.80M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.0%
Year over year · more shares
Revenue CAGR (3Y)
+1.8%
Revenue CAGR (5Y)
+14.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-116.6%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.11M
Latest balance sheet
Cash & equivalents
$1.43M
Total assets
$6.54M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.40M
Capital expenditures (TTM)
—
R&D (TTM)
$1.84M
SG&A (TTM)
—
Stock compensation (TTM)
$648,362
R&D / revenue
48.4%
Stock compensation / revenue
17.1%

Ownership (13F)

9 metrics
13F filers
39
13F filer change QoQ
+2
Institutional ownership
12.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
3.7%
Private-fund adviser ownership
3.4%
Active holders' share change QoQ
-12.1%
Holder tenure
9.0
Price vs estimated holder cost
-27.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.3%

Short interest

3 metrics
Short interest
0.5%
Latest settlement · 1.7 days to cover
Days to cover
1.7d
Short-squeeze score
44 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1213809 CUSIP 26745T101 13F (30d) 18 filings 18 filers Visit website Investor relations